Tara Lin

29PUBLICATIONS
144CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsData qualityGene and molecular therapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Jul 28, 2026
OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

|Jul 03, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

|Jun 02, 2026
Near-Real-Time Clinical Trial Accrual Dashboard in a National Cancer Institute-Designated Cancer Center: Mixed Methods Implementation Study.

|Jun 02, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

|Feb 02, 2026
CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

Shai Shimony, H Moses Murdock, Julia H Keating

|Nov 26, 2025
CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis.

Joshua D Mitchell, Michael Pfeiffer, John Boehmer

Pageof 5

Frequent Collaborators

7 joint publications

Yazan F Madanat

7 joint publications

Brian J Druker

7 joint publications

Alice S Mims

6 joint publications

Joshua Zeidner